BR0110748A - Plataforma de nanodispositivo multifuncional - Google Patents

Plataforma de nanodispositivo multifuncional

Info

Publication number
BR0110748A
BR0110748A BR0110748-8A BR0110748A BR0110748A BR 0110748 A BR0110748 A BR 0110748A BR 0110748 A BR0110748 A BR 0110748A BR 0110748 A BR0110748 A BR 0110748A
Authority
BR
Brazil
Prior art keywords
multifunctional
therapy
compositions
therapeutic
present
Prior art date
Application number
BR0110748-8A
Other languages
English (en)
Inventor
James R Baker Jr
Donald A Tomalia
Original Assignee
Univ Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan filed Critical Univ Michigan
Publication of BR0110748A publication Critical patent/BR0110748A/pt

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
    • C08G83/002—Dendritic macromolecules
    • C08G83/003—Dendrimers
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L101/00—Compositions of unspecified macromolecular compounds
    • C08L101/005—Dendritic macromolecules

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Nanotechnology (AREA)
  • Biochemistry (AREA)
  • Polymers & Plastics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"PLATAFORMA DE NANODISPOSITIVO MULTIFUNCIONAL". A presente invenção refere-se a conjuntos de diagnóstico e terapêutico, novos. Mais particularmente a presente invenção é dirigida a sistemas e composições multifuncionais baseados em dendrímero para uso em diagnóstico e terapia de doença (por exemplo, diagnóstico e terapia de câncer). As composições e sistemas compreendem genericamente dois ou mais componentes separados para direcionar, formar imagem, sentir e/ou acionar a liberação de um material terapêutico ou de diagnóstico e monitorar a resposta à terapia de uma célula ou tecido (por exemplo, um tumor).
BR0110748-8A 2000-05-12 2001-05-11 Plataforma de nanodispositivo multifuncional BR0110748A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/570,198 US6471968B1 (en) 2000-05-12 2000-05-12 Multifunctional nanodevice platform
PCT/US2001/015204 WO2001087348A2 (en) 2000-05-12 2001-05-11 Multifunctional nanodevice platform

Publications (1)

Publication Number Publication Date
BR0110748A true BR0110748A (pt) 2004-08-31

Family

ID=24278661

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0110748-8A BR0110748A (pt) 2000-05-12 2001-05-11 Plataforma de nanodispositivo multifuncional

Country Status (9)

Country Link
US (2) US6471968B1 (pt)
EP (1) EP1301211A2 (pt)
JP (1) JP2004515457A (pt)
CN (2) CN101347623A (pt)
AU (1) AU2001261420A1 (pt)
BR (1) BR0110748A (pt)
CA (1) CA2408535C (pt)
MX (1) MXPA02011142A (pt)
WO (1) WO2001087348A2 (pt)

Families Citing this family (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040072937A1 (en) * 2001-02-10 2004-04-15 Tomalia Donald A. Nanocomposites of dendritic polymers
US6494879B2 (en) 1998-10-15 2002-12-17 Scimed Life Systems, Inc. Treating urinary retention
US20030129654A1 (en) * 1999-04-15 2003-07-10 Ilya Ravkin Coded particles for multiplexed analysis of biological samples
US20030207249A1 (en) * 1999-04-15 2003-11-06 Beske Oren E. Connection of cells to substrates using association pairs
US20030166015A1 (en) * 1999-04-15 2003-09-04 Zarowitz Michael A. Multiplexed analysis of cell-substrate interactions
US20040018485A1 (en) * 1999-04-15 2004-01-29 Ilya Ravkin Multiplexed analysis of cells
AU782697B2 (en) * 1999-12-16 2005-08-18 Monsanto Technology Llc DNA constructs for expression of heterologous polypeptides in plants
US20040146918A1 (en) * 2000-02-18 2004-07-29 Weiner Michael L. Hybrid nucleic acid assembly
ES2307619T3 (es) * 2000-05-19 2008-12-01 Amylin Pharmaceuticals, Inc. Tratamiento del sindrome coronario agudo con glp-1.
JP2004537712A (ja) * 2000-10-18 2004-12-16 バーチャル・アレイズ・インコーポレーテッド 多重細胞分析システム
CN100543036C (zh) 2002-05-06 2009-09-23 得克萨斯州大学系统董事会 递送治疗或诊断试剂的导向蛋白质
US7549985B2 (en) * 2002-06-26 2009-06-23 The Regents Of The University Of Michigan Method and system to create and acoustically manipulate a microbubble
WO2004025284A1 (en) * 2002-08-29 2004-03-25 The Regents Of The University Of Michigan Laser-based method and system for enhanced optical breakdown
US7367948B2 (en) * 2002-08-29 2008-05-06 The Regents Of The University Of Michigan Acoustic monitoring method and system in laser-induced optical breakdown (LIOB)
US7474919B2 (en) * 2002-08-29 2009-01-06 The Regents Of The University Of Michigan Laser-based method and system for enhancing optical breakdown
AU2003256038A1 (en) * 2002-08-30 2004-03-19 Ramot At Tel Aviv University Ltd. Self-immolative dendrimers releasing many active moieties upon a single activating event
US20050282814A1 (en) * 2002-10-03 2005-12-22 Targegen, Inc. Vasculostatic agents and methods of use thereof
MXPA05003477A (es) * 2002-10-03 2005-07-22 Targegen Inc Agentes vasculo-estaticos y metodos de uso de los mismos.
WO2004041310A1 (en) * 2002-11-08 2004-05-21 Danmarks Fødevareforskning Preparation of chemically well-defined carbohydrate dendrimer conjugates
WO2004064751A2 (en) * 2003-01-16 2004-08-05 St. Johns University New York Nanoparticle based stabilization of ir fluorescent dyes
US20060239907A1 (en) * 2003-06-03 2006-10-26 The Trustees Of The University Of Pennsylvania Stealthy nano agents
WO2005018681A1 (en) * 2003-06-03 2005-03-03 The Trustees Of The University Of Pennsylvania Nanoradiopharmaceuticals and methods of use
US20040258614A1 (en) * 2003-06-20 2004-12-23 University Of Maryland, Baltimore Microparticles for microarterial imaging and radiotherapy
US20050008861A1 (en) * 2003-07-08 2005-01-13 Nanoproducts Corporation Silver comprising nanoparticles and related nanotechnology
US7488451B2 (en) 2003-09-15 2009-02-10 Millipore Corporation Systems for particle manipulation
WO2005036180A1 (en) * 2003-10-08 2005-04-21 The Government Of The United States Of America As Represented By The Secretary Of Department Of Health And Human Services Analysis methods using biomarkers concentrated with biomarkers attractant molecules
US7335795B2 (en) * 2004-03-22 2008-02-26 Ilypsa, Inc. Crosslinked amine polymers
US7449605B2 (en) * 2003-11-03 2008-11-11 Ilypsa, Inc. Crosslinked amine polymers
US7767768B2 (en) * 2003-11-03 2010-08-03 Ilypsa, Inc. Crosslinked amine polymers
US7459502B2 (en) * 2003-11-03 2008-12-02 Ilypsa, Inc. Pharmaceutical compositions comprising crosslinked polyamine polymers
US7608674B2 (en) 2003-11-03 2009-10-27 Ilypsa, Inc. Pharmaceutical compositions comprising cross-linked small molecule amine polymers
US7385012B2 (en) * 2003-11-03 2008-06-10 Ilypsa, Inc. Polyamine polymers
WO2005062854A2 (en) 2003-12-19 2005-07-14 University Of Cincinnati Polyamides for nucleic acid delivery
US20050171424A1 (en) * 2004-01-13 2005-08-04 The Gov. Of The Usa As Rep. By The Secretary Of The Dept. Of Health And Human Services Methods for imaging the lymphatic system using dendrimer-based contrast agents
EP2543376A1 (en) * 2004-04-08 2013-01-09 Targegen, Inc. Benzotriazine inhibitors of kinases
WO2005102396A2 (en) * 2004-04-20 2005-11-03 Emory University Multimodality nanostructures, methods of fabrication thereof, and methods of use thereof
EP1766061B1 (en) * 2004-05-20 2013-07-17 Quest Diagnostics Investments Incorporated Single label comparative hybridization
US20070009980A1 (en) * 2004-06-01 2007-01-11 Applera Corporation Continuous fluorogenic analyte assays with dendritic amplification of signal
EP1796537A4 (en) * 2004-08-25 2012-03-07 Univ Michigan DENDRIMER COMPOSITIONS AND METHODS OF USE THEREOF
WO2006024034A1 (en) 2004-08-25 2006-03-02 Targegen, Inc. Heterocyclic compounds and methods of use
KR100604976B1 (ko) 2004-09-03 2006-07-28 학교법인연세대학교 다작용기 리간드로 안정화된 수용성 나노입자
KR100652251B1 (ko) 2004-09-03 2006-12-01 학교법인연세대학교 다작용기 리간드를 이용한 나노입자의 표면 개질 및수용성 나노입자의 제조방법
US8354093B2 (en) 2004-10-15 2013-01-15 Washington University Cell permeable nanoconjugates of shell-crosslinked knedel (SCK) and peptide nucleic acids (“PNAs”) with uniquely expressed or over-expressed mRNA targeting sequences for early diagnosis and therapy of cancer
PL1842557T3 (pl) 2004-12-22 2014-04-30 Nitto Denko Corp Nośnik leku i zestaw z nośnikiem leu do hamowania zwłóknienia
US20120269886A1 (en) 2004-12-22 2012-10-25 Nitto Denko Corporation Therapeutic agent for pulmonary fibrosis
US20060204443A1 (en) * 2005-03-11 2006-09-14 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services Methods for tumor treatment using dendrimer conjugates
ES2731298T3 (es) 2005-05-27 2019-11-14 Univ North Carolina Chapel Hill Partículas de liberación de óxido nítrico para agentes terapéuticos de óxido nítrico y aplicaciones biomédicas
US20060269480A1 (en) * 2005-05-31 2006-11-30 Ramot At Tel Aviv University Ltd. Multi-triggered self-immolative dendritic compounds
EP1893216A4 (en) * 2005-06-08 2012-08-08 Targegen Inc METHOD AND COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES
JP5368793B2 (ja) 2005-07-18 2013-12-18 ユニバーシティ オブ マサチューセッツ ロウエル ナノエマルジョンを製造および使用するための組成物および方法
WO2007016466A2 (en) * 2005-07-29 2007-02-08 Sloan-Kettering Institute For Cancer Research Single wall nanotube constructs and uses therefor
US20070041934A1 (en) * 2005-08-12 2007-02-22 Regents Of The University Of Michigan Dendrimer based compositions and methods of using the same
WO2007035311A2 (en) * 2005-09-16 2007-03-29 University Of Massachusetts Lowell Anti-oxidant synergy formulation nanoemulsions to treat cancer
CA2626105C (en) 2005-10-18 2015-08-18 Starpharma Pty Limited Microbicidal dendrimer composition delivery system
US8566038B2 (en) * 2005-10-21 2013-10-22 The Regents Of The University Of California Compositions and methods for analyzing immobilized nucleic acids
DK1940916T3 (en) 2005-10-25 2017-03-20 Starpharma Pty Ltd MACROMOLECULAR COMPOUNDS WITH CONTROLLED STOCHIOMETRY
PL1951684T3 (pl) 2005-11-01 2017-03-31 Targegen, Inc. Biarylowe meta-pirymidynowe inhibitory kinaz
US8133900B2 (en) * 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
US8604042B2 (en) * 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US9012620B2 (en) 2005-11-25 2015-04-21 Mologen Ag DNA constructs for specific inhibition of gene expression by RNA interference
MX2008006750A (es) 2005-12-01 2008-09-03 Univ Massachusetts Lowell Nanoemulsiones de botulinum.
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
WO2007067733A2 (en) * 2005-12-09 2007-06-14 Massachusetts Institute Of Technology Compositions and methods to monitor rna delivery to cells
US9572886B2 (en) 2005-12-22 2017-02-21 Nitto Denko Corporation Agent for treating myelofibrosis
WO2007082331A1 (en) * 2006-01-20 2007-07-26 Starpharma Pty Limited Modified macromolecule
US9603941B2 (en) * 2006-01-24 2017-03-28 Minghui Chai Method of preparing dendritic drugs
US8492098B2 (en) 2006-02-21 2013-07-23 The Trustees Of Tufts College Methods and arrays for target analyte detection and determination of reaction components that affect a reaction
JP5322918B2 (ja) 2006-03-22 2013-10-23 スターファーマ・プロプライエタリー・リミテッド 避妊用組成物
US7691858B2 (en) * 2006-04-25 2010-04-06 Targegen, Inc. Kinase inhibitors and methods of use thereof
US8501478B2 (en) 2006-06-15 2013-08-06 University Of Cincinnati Trehalose click polymers for delivery of biologically active molecules
WO2008008356A2 (en) * 2006-07-11 2008-01-17 The Regents Of The University Of Michigan Fret-based apoptosis detector
WO2008017125A1 (en) 2006-08-11 2008-02-14 Starpharma Pty Ltd Targeted polylysine dendrimer therapeutic agent
EP2099429A2 (en) 2006-12-01 2009-09-16 Anterios, Inc. Micellar nanoparticles comprising botulinum toxin
US20100172943A1 (en) 2006-12-01 2010-07-08 Anterios, Inc. Peptide nanoparticles and uses therefor
WO2008073856A2 (en) * 2006-12-08 2008-06-19 Massachusetts Institute Of Technology Delivery of nanoparticles and/or agents to cells
US8642093B2 (en) 2007-10-30 2014-02-04 The Invention Science Fund I, Llc Methods and systems for use of photolyzable nitric oxide donors
US8221690B2 (en) 2007-10-30 2012-07-17 The Invention Science Fund I, Llc Systems and devices that utilize photolyzable nitric oxide donors
US20090112197A1 (en) 2007-10-30 2009-04-30 Searete Llc Devices configured to facilitate release of nitric oxide
US7862598B2 (en) * 2007-10-30 2011-01-04 The Invention Science Fund I, Llc Devices and systems that deliver nitric oxide
EP2109689A4 (en) * 2007-02-07 2010-02-10 Perscitus Biosciences Llc DETECTION OF THE PROXIMITY OF A MOLECULE
TWI407971B (zh) 2007-03-30 2013-09-11 Nitto Denko Corp Cancer cells and tumor-related fibroblasts
AU2008275501A1 (en) * 2007-04-19 2009-01-15 The Regents Of The University Of Michigan Dendrimer based compositions and methods of using the same
CA2688415C (en) 2007-05-31 2015-11-10 Anterios, Inc. Nucleic acid nanoparticles and uses therefor
KR100904207B1 (ko) * 2007-06-01 2009-06-25 (주) 태웅메디칼 스텐트용 약물 방출 코팅제, 그의 제조방법 및 이 코팅제로 코팅된 약물 방출 스텐트
US7507539B2 (en) 2007-07-30 2009-03-24 Quest Diagnostics Investments Incorporated Substractive single label comparative hybridization
WO2009026540A1 (en) * 2007-08-22 2009-02-26 Colorado School Of Mines Lanthanide nanoparticle conjugates and uses thereof
US8003621B2 (en) 2007-09-14 2011-08-23 Nitto Denko Corporation Drug carriers
US10080823B2 (en) 2007-10-30 2018-09-25 Gearbox Llc Substrates for nitric oxide releasing devices
US7846400B2 (en) 2007-10-30 2010-12-07 The Invention Science Fund I, Llc Substrates for nitric oxide releasing devices
US8877508B2 (en) 2007-10-30 2014-11-04 The Invention Science Fund I, Llc Devices and systems that deliver nitric oxide
US7897399B2 (en) 2007-10-30 2011-03-01 The Invention Science Fund I, Llc Nitric oxide sensors and systems
US8980332B2 (en) 2007-10-30 2015-03-17 The Invention Science Fund I, Llc Methods and systems for use of photolyzable nitric oxide donors
US20110105408A1 (en) * 2008-02-22 2011-05-05 Inter-K Pty Limited Therapeutic peptides
CA2711108C (en) 2008-02-27 2016-11-22 Kci Licensing Inc. System and method for healing a wound at a tissue site
WO2009151687A2 (en) 2008-03-12 2009-12-17 The Regents Of The University Of Michigan Dendrimer conjugates
WO2010096464A1 (en) 2009-02-18 2010-08-26 Boyes Stephen G Gold/lanthanide nanoparticle conjugates and uses thereof
US20100069821A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Ex vivo modifiable medicament release-sites final dosage form
US20100068153A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Ex vivo activatable final dosage form
US20100068278A1 (en) 2008-09-16 2010-03-18 Searete Llc, A Limited Liablity Corporation Of The State Of Delaware Ex vivo modifiable medicament release-associations
WO2010039861A2 (en) 2008-09-30 2010-04-08 The Regents Of The University Of Michigan Dendrimer conjugates
US9017644B2 (en) 2008-11-07 2015-04-28 The Regents Of The University Of Michigan Methods of treating autoimmune disorders and/or inflammatory disorders
US20100158850A1 (en) * 2008-12-23 2010-06-24 The Regents Of The University Of Michigan Dendrimer based modular platforms
US20120244205A1 (en) * 2009-08-25 2012-09-27 The Regents Of The University Of California Nanotechnological Delivery of Microbicides and Other Substances
US20120219496A1 (en) * 2009-09-02 2012-08-30 Andrew Tsourkas Gadolinium-linked nanoclusters
US8828383B2 (en) 2009-09-23 2014-09-09 The Regents Of The University Of California Nanocarriers with multi-photon response elements
US8945508B2 (en) 2009-10-13 2015-02-03 The Regents Of The University Of Michigan Dendrimer compositions and methods of synthesis
CN101695476B (zh) * 2009-10-26 2011-10-19 吉林大学 医用纳米粒子的制备方法
US8912323B2 (en) 2009-10-30 2014-12-16 The Regents Of The University Of Michigan Multifunctional small molecules
WO2011072290A2 (en) * 2009-12-11 2011-06-16 The Regents Of The University Of Michigan Targeted dendrimer-drug conjugates
EP2526119B1 (en) 2010-01-19 2018-05-30 President and Fellows of Harvard College Engineered opsonin for pathogen detection and treatment
US8758778B2 (en) 2010-09-16 2014-06-24 The Regents Of The University Of California Polymeric nano-carriers with a linear dual response mechanism and uses thereof
CA2816957A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
KR20190092629A (ko) 2011-02-07 2019-08-07 라이프 테크놀로지스 코포레이션 감수성 화합물을 안정화시키는 조성물 및 방법
WO2013009701A2 (en) 2011-07-08 2013-01-17 The University Of North Carolina At Chapel Hill Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders
JP2014523914A (ja) 2011-07-18 2014-09-18 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 操作された微生物標的化分子およびその使用
WO2013085718A1 (en) 2011-12-08 2013-06-13 The Regents Of The University Of Michigan Multifunctional small molecules
WO2014036194A1 (en) 2012-08-28 2014-03-06 The Regents Of The University Of California Polymeric nanocarriers with light-triggered release mechanism
US10551379B2 (en) * 2013-03-15 2020-02-04 President And Fellows Of Harvard College Methods and compositions for improving detection and/or capture of a target entity
JP6649250B2 (ja) 2013-05-21 2020-02-19 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 操作されたヘム結合性構成物およびその使用
JP6297440B2 (ja) * 2013-07-31 2018-03-20 キヤノンメディカルシステムズ株式会社 造影剤
EP3546474B1 (en) 2013-12-18 2021-07-07 President and Fellows of Harvard College Crp capture/detection of gram positive bacteria
CN103675288B (zh) * 2013-12-26 2015-10-28 泸州医学院 一种血小板标记物及其制备方法
JP6073508B2 (ja) 2014-01-13 2017-02-01 ベルハジ−タハール ハフィド デンドリマー組成物、合成方法、及びそれらの使用
WO2015109255A1 (en) * 2014-01-16 2015-07-23 Genisphere, Llc Lateral flow assays using dna dendrimers
KR101566345B1 (ko) * 2014-03-21 2015-11-23 한국생명공학연구원 다가성 리간드의 내부 표면작용기와 암 표적 리간드 단위의 비율을 조절하여 암 진단 효율을 향상시키는 방법
CN108289928A (zh) 2015-08-06 2018-07-17 哈佛大学校长及研究员协会 改进的微生物-结合分子和其用途
WO2017044768A1 (en) * 2015-09-10 2017-03-16 Massachusetts Institute Of Technology Rna triple helix structures, compositions, and methods
MA39136B2 (fr) * 2016-06-21 2021-04-30 Univ Euro Mediterraneenne De Fes Nouvelles macromolecules geantes : les poly - dendrimeres
EP3541358A1 (en) 2016-11-21 2019-09-25 Eirion Therapeutics, Inc. Transdermal delivery of large agents
WO2018194755A1 (en) * 2017-04-17 2018-10-25 University Of Southern California Method to generate biocompatible dendritic polymers for analyte detection with multimodal labeling and signal amplification
CA3106568A1 (en) * 2018-07-19 2020-01-23 Starpharma Pty Ltd Therapeutic dendrimer

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4558120A (en) 1983-01-07 1985-12-10 The Dow Chemical Company Dense star polymer
US4568737A (en) 1983-01-07 1986-02-04 The Dow Chemical Company Dense star polymers and dendrimers
US4737550A (en) 1983-01-07 1988-04-12 The Dow Chemical Company Bridged dense star polymers
US4507466A (en) 1983-01-07 1985-03-26 The Dow Chemical Corporation Dense star polymers having core, core branches, terminal groups
US4631337A (en) 1983-01-07 1986-12-23 The Dow Chemical Company Hydrolytically-stable dense star polyamine
US4939240A (en) 1983-03-04 1990-07-03 Health Research, Inc. Monoclonal antibodies to human breast carcinoma cells and their use in diagnosis and therapy
US4587329A (en) 1984-08-17 1986-05-06 The Dow Chemical Company Dense star polymers having two dimensional molecular diameter
US4708930A (en) 1984-11-09 1987-11-24 Coulter Corporation Monoclonal antibody to a human carcinoma tumor associated antigen
US4918164A (en) 1987-09-10 1990-04-17 Oncogen Tumor immunotherapy using anti-idiotypic antibodies
US4743543A (en) 1985-09-09 1988-05-10 Coulter Corporation Method for enhancing and/or accelerating immunoassay detection of human carcinoma tumor associated antigen in a pathology sample
US4871779A (en) 1985-12-23 1989-10-03 The Dow Chemical Company Ion exchange/chelation resins containing dense star polymers having ion exchange or chelate capabilities
US4694064A (en) 1986-02-28 1987-09-15 The Dow Chemical Company Rod-shaped dendrimer
US4713975A (en) 1986-05-30 1987-12-22 The Dow Chemical Company Dense star polymers for calibrating/characterizing sub-micron apertures
JPS6319561A (ja) 1986-07-11 1988-01-27 Kyowa Hakko Kogyo Co Ltd 抗ヒト肺癌単クロ−ン性抗体
US5560929A (en) 1986-08-18 1996-10-01 The Dow Chemical Company Structured copolymers and their use as absorbents, gels and carriers of metal ions
ES2054678T5 (es) * 1986-08-18 1997-09-16 Dow Chemical Co Conjugados estrella.
US5527524A (en) 1986-08-18 1996-06-18 The Dow Chemical Company Dense star polymer conjugates
US5338532A (en) 1986-08-18 1994-08-16 The Dow Chemical Company Starburst conjugates
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4921790A (en) 1987-04-24 1990-05-01 Research Corporation Tumor specific assay for CA125 ovarian cancer antigen
ATE162308T1 (de) 1987-07-15 1998-01-15 Us Health Monoklonale antikörper der zweiten generation mit bindungsspezifität für tag-72 und menschliche karzinome sowie methoden zu ihrer anwendung
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5053489A (en) 1988-01-29 1991-10-01 Dana-Farber Cancer Institute, Inc. Genetically engineered polypeptides with determinants of the human DF3 breast carcinoma-associated antigen
US4963484A (en) 1988-01-29 1990-10-16 Dana-Farber Cancer Institute, Inc. Genetically engineered polypeptides with determinants of the human DF3 breast carcinoma-associated antigen
US4857599A (en) 1988-02-08 1989-08-15 The Dow Chemical Company Modified dense star polymers
US4914021A (en) 1988-03-04 1990-04-03 New England Deaconess Hospital Corporation Carcinoma orosomucoid-related antigen, a monoclonal antibody thereto, and their uses
US4921789A (en) 1988-04-20 1990-05-01 New England Deaconess Hospital Corporation Marker for colorectal carcinoma and methods of detecting the same
JPH0734015B2 (ja) 1988-04-25 1995-04-12 和光純薬工業株式会社 微量成分の新規測定法
SE463851B (sv) 1988-09-02 1991-02-04 Amsu Ltd Komposition foer behandling av erektil dysfunktion via uretra
US5318529A (en) 1989-09-06 1994-06-07 Boston Scientific Corporation Angioplasty balloon catheter and adaptor
US5110911A (en) 1989-11-02 1992-05-05 Biomira, Inc. Human tumor-associated thomsen-friedenreich antigen
US5674192A (en) 1990-12-28 1997-10-07 Boston Scientific Corporation Drug delivery
US5843089A (en) 1990-12-28 1998-12-01 Boston Scientific Corporation Stent lining
DK0533838T3 (da) 1990-06-11 1998-02-23 Nexstar Pharmaceuticals Inc Nukleinsyreligander
US5874218A (en) 1990-06-11 1999-02-23 Nexstar Pharmaceuticals, Inc. Method for detecting a target compound in a substance using a nucleic acid ligand
US5861254A (en) 1997-01-31 1999-01-19 Nexstar Pharmaceuticals, Inc. Flow cell SELEX
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5631329A (en) 1990-08-27 1997-05-20 Dendritech, Inc. Process for producing hyper-comb-branched polymers
US5773527A (en) 1990-08-27 1998-06-30 Dendritech, Inc. Non-crosslinked, polybranched polymers
US5876445A (en) 1991-10-09 1999-03-02 Boston Scientific Corporation Medical stents for body lumens exhibiting peristaltic motion
ATE239506T1 (de) 1992-03-05 2003-05-15 Univ Texas Verwendung von immunokonjugate zur diagnose und/oder therapie der vaskularisierten tumoren
US6113946A (en) 1992-04-03 2000-09-05 The Regents Of The University Of California Self-assembling polynucleotide delivery system comprising dendrimer polycations
US5354308A (en) 1992-05-01 1994-10-11 Beth Israel Hospital Association Metal wire stent
DE69327229T2 (de) 1992-12-11 2000-03-30 Dow Chemical Co Multivalente einkettige Antikörper
US5387617A (en) 1993-01-22 1995-02-07 The Dow Chemical Company Small cell foams and blends and a process for their preparation
DE69432926T2 (de) 1993-02-05 2004-05-13 Epigen, Inc., Wellesley Humanes carcinoma-antigen (hca), hca antikörper, hca immunoassays, aufzeichnungsmethoden und therapy
ES2132392T3 (es) 1993-02-24 1999-08-16 Dade Behring Inc Inmovilizacion de reactivos de ensayo de enlace especifico.
US5898005A (en) * 1993-02-24 1999-04-27 Dade Behring Inc. Rapid detection of analytes with receptors immobilized on soluble submicron particles
US5913894A (en) 1994-12-05 1999-06-22 Meadox Medicals, Inc. Solid woven tubular prosthesis
JP3694524B2 (ja) 1993-08-23 2005-09-14 ボストン サイエンティフィック コーポレイション 改良形バルーンカテーテル
US5609627A (en) 1994-02-09 1997-03-11 Boston Scientific Technology, Inc. Method for delivering a bifurcated endoluminal prosthesis
KR100357839B1 (ko) 1994-03-07 2003-08-02 더 다우 케미칼 캄파니 생체활성및/또는표적화된덴드리머콘쥬게이트
US5733303A (en) 1994-03-17 1998-03-31 Medinol Ltd. Flexible expandable stent
JP3647456B2 (ja) 1994-04-29 2005-05-11 ボストン・サイエンティフィック・コーポレーション 医療用人工ステント及びその製造方法
US5857998A (en) 1994-06-30 1999-01-12 Boston Scientific Corporation Stent and therapeutic delivery system
US5620417A (en) 1994-07-07 1997-04-15 Cardiovascular Imaging Systems Incorporated Rapid exchange delivery catheter
US5755722A (en) 1994-12-22 1998-05-26 Boston Scientific Corporation Stent placement device with medication dispenser and method
US6013443A (en) 1995-05-03 2000-01-11 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue SELEX
DE69635659T2 (de) 1995-06-01 2006-07-06 Meadox Medicals, Inc. Implantierbare intraluminale prothese
US6083708A (en) * 1995-08-11 2000-07-04 Dade Behring Inc. Polypeptide: dendrimer complexes
US5795582A (en) 1996-02-07 1998-08-18 Novavax, Inc. Adjuvant properties of poly (amidoamine) dendrimers
US5792105A (en) 1996-09-11 1998-08-11 Boston Scientific Corporation Multichannel balloon catheter for delivering fluid
US5868719A (en) 1997-01-15 1999-02-09 Boston Scientific Corporation Drug delivery balloon catheter device
US5933145A (en) 1997-04-17 1999-08-03 Microsoft Corporation Method and system for visually indicating a selection query
US6143558A (en) 1997-07-08 2000-11-07 The Regents Of The University Of Michigan Optical fiberless sensors for analyzing cellular analytes
US5902863A (en) 1997-07-21 1999-05-11 Dow Corning Corporation Dendrimer-based networks containing lyophilic organosilicon and hydrophilic polyamidoamine nanoscopic domains
US5866561A (en) 1997-08-21 1999-02-02 Scimed Life Systems, Inc. Local delivery of estrogen for angiogenesis
GB9718129D0 (en) * 1997-08-27 1997-10-29 Isis Innovation Branched structures
US5908413A (en) 1997-10-03 1999-06-01 Scimed Life Systems, Inc. Radiopaque catheter and method of manufacture thereof
GB9811403D0 (en) * 1998-05-27 1998-07-22 Isis Innovation Polynucleotide multimers and their use in hybridisation assays
CA2376619A1 (en) * 1999-06-29 2001-01-11 Dako A/S Detection using dendrimers bearing labels and probes

Also Published As

Publication number Publication date
CN1471407A (zh) 2004-01-28
US20020165179A1 (en) 2002-11-07
WO2001087348A3 (en) 2002-10-31
AU2001261420A1 (en) 2001-11-26
MXPA02011142A (es) 2004-06-22
CN101347623A (zh) 2009-01-21
CA2408535C (en) 2009-08-11
US6471968B1 (en) 2002-10-29
JP2004515457A (ja) 2004-05-27
EP1301211A2 (en) 2003-04-16
CA2408535A1 (en) 2001-11-22
WO2001087348A2 (en) 2001-11-22

Similar Documents

Publication Publication Date Title
BR0110748A (pt) Plataforma de nanodispositivo multifuncional
BR0115150A (pt) Radiofarmacêuticos para diagnosticar doença de alzheimer
BR0210886A (pt) Composto, composição farmacêutica, uso de um composto, e, métodos de geração de imagens, de monitoração do efeito do tratamento de um corpo humano ou animal com uma droga para combater uma condição associada com câncer e de tratamento de câncer ou de uma doença relacionada em um corpo humano ou animal
BR9604786A (pt) Composição formulação para uso diagnóstico ou terapêutico e processos para preparar uma composiç o de lipídeo estabilizada e uma formulação par uso diagnóstico ou terapêutico para proporcíonar uma imagem de uma regi o interna de um paciente para diagnosticar a presença de tecido doente dentro de um paciente e para liberar terapeuticamente um agente bioativo
WO2006033766A3 (en) Dendrimer based compositions and methods of using the same
BRPI0515175A (pt) método para radiofluoração, composto, composição radiofarmacêutica, uso de um conjugado radiorrotulado ou um sal do mesmo, método para diagnose ou formação de imagem in vivo de uma doença ou condição associada com a angiogênese, e, método para monitorar o efeito do tratamento de um corpo humano ou animal com um medicamento para combater uma condição associada com cáncer
BR0317747A (pt) Método de tratamento terapêutico concomitante de um indivìduo, composição farmacêutica, kit, uso de um primeiro agente e um segundo agente, e, métodos de prevenir ou tratar uma doença relacionada com amilóide-b, doença de alzheimer e insuficiência cognitiva suave
BR9914638A (pt) Composto, método para a preparação do mesmo, composição farmacêutica, uso de um composto, e, método para o tratamento de um distúrbio ou doença de um corpo de animal vivo
TR200001795T2 (tr) 1-İkameli-1-Aminometil-sikloalkan türevleri (=Gabapentin analogları), bunların hazırlanması ve nörolojik bozuklukların tedavisinde kullanımı.
DE60331236D1 (de) Orale zusammensetzungen zur behandlung von diabetes
DE69942614D1 (de) Vorrichtung zur diagnose und therapie von elektrophysiologischen krankheiten
BRPI0408063A (pt) métodos e composições envolvendo mda-7
WO2005048950A3 (en) Tumor and infectious disease therapeutic compositions
TR200101633T2 (tr) Farmasötik bileşim
PT832081E (pt) Compostos biciclicos aromaticos
SI1667947T1 (sl) Postopki 11C-radiooznačevanja fenotiazina in fenotiazinu podobnih spojin
BR0213684A (pt) Uso de antagonistas do receptor de endotelina para o tratamento de doenças tumorìgenas
NZ328874A (en) Heterocyclic biaryl compounds and their use in pharmaceutical compositions for treatment of dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders
CL2004001068A1 (es) Compuestos derivados de 2,3,4,5-tetrahidrobenzo[f][1,4]oxazepina; procedimientos de preparacion; composicion farmaceutica que los contiene y su uso en la elaboracion de un medicamento util para el tratamiento de la enfermedad de alzheimer.
BR9912816A (pt) Composição terapêutica à base de flavonóides, tencionada para uso no tratamento de tumores por agentes citotóxicos
BR0110512A (pt) Preparação para medir a taxa de esvaziamento gástrico
BR9904890A (pt) "compostos de heteroetinileno, composição farmacêutica, composição cosmética e utilização de uma composição cosmética"
KR960028907A (ko) 암환자를 치료하기 위한 세트랄린의 용도
DK1332764T3 (da) Mucoadhæsivt, termoresponsivt lægemiddel-bærer-præparat
ITBO20030261A1 (it) Unita'di irraggiamento luminoso per diagnosi e cura di problemi cutanei.

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.

B15K Others concerning applications: alteration of classification

Ipc: B82Y 5/00 (2011.01), A61K 41/00 (2006.01), A61K 47